Table 1.
Incidence rate of SARS-CoV-2 infection after the first and second doses in people with a history of COVID-19 vaccination.
| First author | Country | Type of vaccines | Type of study | Group of study | SARS-COV 2 incidence | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Partial vaccinated | Unvaccinated | Rate ratio* | Full vaccinated | Unvaccinated | Rate ratio* | |||||||||
| Cases | Pearson day | Cases | Pearson day | Cases | Pearson day | Cases | Pearson day | |||||||
| Noa Dagan (33) | Israel | BNT162b2 mRNA | Prospective cohort study | Age of ≥16 and older | 3,533 | 2,62,180 | 3,971 | 2,61,625 | 0.888 | - | - | - | - | - |
| Hall V. FFPH (34) | UK | BNT162b2 mRNA | Prospective cohort study | Healthcare workers. | 71 | 87,278 | 977 | 7,10,587 | 0.592 | 9 | 20,978 | 977 | 7,10,587 | 0.312 |
| Massimo Fabiani (35) | Italy | BNT162b2 mRNA | Retrospective cohort | Healthcare workers. | 60 | 73,914 | 128 | 62,331 | 0.395 | 0 | 35,596 | 11 | 14,186 | 0 |
| Eric J. Haas (18) | Israel | BNT162b2 mRNA | Prospective cohort study | Age of 16 and older. | - | - | - | - | 6266 | 20,18,82,183 | 1,09,876 | 12,00,76,136 | 0.034 | |
| M. G. Thompson (36) | USA | BNT162b2 mRNA | Prospective cohort study | Health care workers | 8 | 49,516 | 156 | 1,27,971 | 0.133 | 3 | 1,20,653 | 156 | 1,27,971 | 0.02 |
| Sara Y. Tartof (19) | USA | BNT162b2 mRNA | Retrospective cohort | Health care workers. | 585 | 1,29,86,040 | 1,60,280 | 44,95,93,130 | 0.126 | 3414 | 10,94,42,695 | 1,60,280 | 44,95,93,130 | 0.088 |
| Madhumita Shrotri (37) | UK | BNT162b2 mRNA | Prospective cohort study | Aged 65 years and older | 50 | 17,690 | 723 | 3,38,003 | 1.321 | - | - | - | - | - |
| Yoel Angel (11) | Israel | BNT162b2 mRNA | Retrospective cohort | Healthcare workers | 68 | 1,17,389 | 45 | 15,091 | 0.194 | 27 | 1,68,571 | 55 | 25,359 | 0.074 |
| Colin Pawlowski (38) | USA | BNT162b2 mRNA | Retrospective cohort | Aged ≥18 years. | 401 | 29,42,986 | 1,232 | 28,51,069 | 0.315 | 82 | 19,14,500 | 563 | 18,28,464 | 0.139 |
| Gili Regev-Yochay (39) | Israel | BNT162b2 mRNA | Prospective cohort study | Healthcare workers | 30 | 54,832 | 115 | 1,99,126 | 0.947 | 19 | 3,29,071 | 115 | 1,99,126 | 0.1 |
| Arjun Puranik (40) | USA | BNT162b2 mRNA | Retrospective cohort | Aged ≥18 years | 58 | 1,80,675 | 69 | 1,80,614 | 0.84 | 72 | 23,32,005 | 321 | 25,26,895 | 0.243 |
| Mark A. Katz (41) | Israel | BNT162b2 mRNA | Prospective cohort study | Healthcare workers | - | - | - | - | 4 | 68,574 | 9 | 10,027 | 0.065 | |
| Carmen Cabezas (42) | Catalonia | BNT162b2 mRNA | Prospective cohort study | Healthcare workers | 358 | 55,28,745 | 1,961 | 22,69,003 | 0.075 | 222 | 48,77,162 | 961 | 22,69,003 | 0.107 |
| Aharona Freedman (43) | Israel | BNT162b2 mRNA | Retrospective cohort | Aged ≥16 years | 7,166 | 1,42,89,253 | 1,33,994 | 11,97,01,675 | 0.448 | 1639 | 1,40,60,250 | 95,655 | 8,95,35,711 | 0.109 |
| Galia Zacay (44) | Israel | BNT162b2 mRNA | Retrospective cohort | Aged ≥16 years | 59 | 28,727 | 382 | 71,797 | 0.386 | 15 | 26,260 | 382 | 71,797 | 0.107 |
| Victoria Jane Hall (34) | UK | BNT162b2 mRNA | Prospective cohort study | Healthcare workers | 71 | 87,278 | 977 | 7,10,587 | 0.592 | 9 | 20,978 | 977 | 7,10,587 | 0.312 |
| Hanne-Dorthe Emborg (45) | Denmark | BNT162b2 mRNA | Prospective cohort study | Prioritized risk groups, | 610 | 44,15,441 | 13,297 | 5,51,31,206 | 0.573 | 304 | 1,36,12,638 | 13,297 | 5,51,31,206 | 0.093 |
| Jonas Björk (46) | Sweden | BNT162b2 mRNA | Prospective cohort study | Aged 18-64 years, | 25 | 1,02,830 | 4,155 | 99,02,620 | 0.579 | 8 | 1,33,616 | 4,155 | 99,02,620 | 0.143 |
| Susana Monge (47) | Spain | BNT162b2 mRNA | Prospective cohort study | Aged ≥65 years | 2,690 | 2,18,621 | 22 | 2,128 | 1.19 | 885 | 2,07,774 | 20 | 1,997 | 0.425 |
| Madhumita Shrotri (37) | UK | ChAdOx1 | Prospective cohort study | Aged ≥65 years | 82 | 32,672 | 723 | 3,38,003 | 1.173 | - | - | - | - | - |
| Subhadeep Ghosh (48) | India | ChAdOx1 | Prospective cohort study | Healthcare workers | 1,159 | 4,96,53,918 | 10,061 | 10,65,94,492 | 0.247 | 2512 | 5,86,74,639 | 10,061 | 10,65,94,492 | 0.454 |
| M.G. Thompson (36) | USA | mRNA-1273 | Prospective cohort study | Health care workers | 3 | 31,231 | 156 | 1,27,971 | 0.079 | 2 | 40,394 | 156 | 1,27,971 | 0.041 |
| Colin Pawlowski (38) | USA | mRNA-1273 | Retrospective cohort | Aged ≥18 years. | 97 | 9,46,890 | 303 | 9,27,716 | 0.314 | 7 | 4,95,550 | 101 | 4,78,322 | 0.067 |
| Arjun Puranik (40) | USA | mRNA-1273 | Retrospective cohort | Aged ≥18 years | 74 | 1,80,810 | 69 | 1,80,614 | 1.071 | 38 | 22,14,873 | 321 | 25,26,895 | 0.135 |
| Mark G. Thompson (49) | USA | Combination† | Prospective cohort study | Healthcare workers | 8 | 41,856 | 161 | 1,16,657 | 0.138 | 3 | 78,902 | 161 | 1,16,657 | 0.028 |
| Ashley Fowlkes (50) | USA | Combination† | Prospective cohort study | Healthcare workers | - | - | - | - | 34 | 4,54,832 | 194 | 1,81,357 | 0.07 | |
| Tara C. Bouton (51) | USA | Combination† | Prospective cohort study | Healthcare workers, | 29 | 2,51,790 | 329 | 4,06,387 | 0.142 | - | - | - | - | - |
*
Rate Ratio computed.
†
BNT162b2 mRNA and mRNA-1273 and ChAdOx1.